Early Detection Research Network

CXCL8

Aliases:
This biomarker is also known as:
  • interleukin-8,
  • LUCT,
  • IL8,
  • Protein 3-10C,
  • T cell chemotactic factor,
  • lymphocyte-derived neutrophil-activating factor,
  • emoctakin,
  • Emoctakin,
  • NAP1,
  • NAP-1,
  • LYNAP,
  • IL-8,
  • Neutrophil-activating protein 1,
  • Monocyte-derived neutrophil-activating peptide,
  • CXCL8,
  • C-X-C motif chemokine 8,
  • GCP-1,
  • GCP1,
  • OTTHUMP00000199825,
  • 3-10C,
  • NAF,
  • interleukin 8,
  • T-cell chemotactic factor,
  • Granulocyte chemotactic protein,
  • small inducible cytokine subfamily B, member 8,
  • neutrophil-activating peptide 1,
  • MDNCF,
  • MONAP,
  • beta-thromboglobulin-like protein,
  • chemokine (C-X-C motif) ligand 8,
  • AMCF-I,
  • LECT,

Description…

CXCL8, commonly known as IL8, is a member of the CXC chemokine family. This chemokine functions as a chemoattractant, or chemotactic factor, that attracts neutrophils, basophils, and T-cells, but not monocytes. IL8 is one of the major mediators of the inflammatory response, and is involved in neutrophil activation. It is released from several types of cells in response to an inflammatory stimulus. IL8 also functions as an angiogenic factor. The IL8 gene maps to chromosome 4q, and is found in a chemokine gene cluster along with ten other members of the CXC chemokine gene family. There are several N-terminal processed forms that are produced by proteolytic cleavage after secretion from at least peripheral blood monocytes, leukcocytes and endothelial cells. Among the forms are: IL-8(1-77), IL-8(5-77), IL-8(6-77), IL-8(7-77), IL-8(8-77), IL-8(9-77). IL-8(1-77) is generally referred to as interleukin 8. IL-8(6-77) is the most promiment form.

Datasets

There are no datasets associated with this biomarker.

Attributes
QA State: Curated
Type: Protein
HGNC Name: CXCL8

The following organs have data associated with this biomarker…

Attributes

Phase: One
QA State: Curated

Overview

No additional data available.

Performance Comment

Ninety biomarkers were measured using a series of multiplexed immunoassays and results analyzed by the EDRN data management center splitting the cases and controls into training and validation sets, excluding subjects with DCIS or atypical hyperplasia from the training phase. We found little evidence that any of these markers can discriminate women with invasive cancer from those with benign breast conditions.

Attributes

Phase: Two
QA State: Under Review

Overview

No additional data available.

Performance Comment

Levels of IL8 in exhaled breath condensate indicated acute inflammation but were not indicative of lung cancer.

Attributes

Phase: Two
QA State: Under Review

Overview

IL8 alone was not shown to be a strong predictor of ovarian cancer.

Performance Comment

Despite many promising new markers for ovarian cancer, CA125 remains the single best biomarker in the phase II and phase III specimens tested in this study.

Attributes

Phase: One
QA State: Under Review

Overview

Performance Comment

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.